News & Updates
Showing Oncology articles
Showing
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.
COPD, smoking aggravate complication risk after lung cancer resection
Smoking and chronic obstructive pulmonary disease (COPD) worsen the risk of postoperative pulmonary complications after lung cancer resection, a recent study has found. Focusing on COPD treatment, rather than smoking cessation alone, may be a more optimal approach to improve postoperative outcomes in this population.
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.
T-DXd ups PFS vs T-DM1 in HER2-positive metastatic breast cancer
Trastuzumab deruxtecan (T-DXd) reduces the risk of disease progression or death by 72 percent vs trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer whose disease progressed during or after treatment with an anti–HER-2 antibody, the first interim analysis of the DESTINY-Breast03 trial has shown.
Exclusionary testing most efficient and cost-saving for NSCLC
Exclusionary testing, involving upfront testing for EGFR and ALK followed by next-generation sequencing (NGS) for other genomic alterations (GAs), is the most efficient and cost-saving molecular testing strategy for patients with metastatic non-small-cell lung cancer (NSCLC) in Hong Kong and perhaps East Asia, researchers from the Chinese University of Hong Kong (CUHK) have reported.